1Gary R,,Yusuf S.Overview of randomized trials of angiotensin-converting engyme in-hibitors on mortality and morbidity in patients with heart failure[].The Journal of The American Medical Association.1995
2Cohn JN.Results of Val-HeFT trial[].rd AHA Meeting.
3Mazayev VP,Fomina IG,Kazakov EN,et al.Valsartan in heart fail-ure patients previously untreated with an ACE inhibitor[].International Journal of Cardiology.1998
4Swedberg K,Pfeffer M,Granger C,et al.For the CHARM pro-gramme investigators.Candesartan in heart failure: assessment of re-duction in mortality and morbidity (CHARM): rational and design[].Journal of Cardiac Failure.1999
5Pitt B,Poole-Wilson P,Segal R,et al.Effects of losartan versus cap-topril on mortality in patients with symptomatic heart failure: ratio-nale, design and baseline characterlstics of patients in the losartan heart failure survival study-ELITE Ⅱ[].Journal of Cardiac Failure.1999
6Califf RM,Cohn JN.Cardiac protection: Evolving role of angiotensionreceptor blocker[].AHJ.2000
